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MicroRNAs (miRNAs) are a class of small 
RNAs with diverse regulatory roles. The 
discovery of miRNAs and closely related 
small-interfering RNAs (siRNAs) is a 
watershed moment in biology that has 
changed traditional views of genetic 
regulation and has placed small RNAs 
alongside transcription factors as criti-
cal regulators of gene expression. But 
what regulates these regulators? Recent 
studies indicate that miRNA biogenesis 
can be posttranscriptionally regulated 
by trans-acting factors. The Lin28/let-7 
partnership is the best characterized 
example of the relationship between an 
miRNA and its posttranscriptional regu-
lator and may shed light on the posttran-
scriptional regulation of other miRNAs. 
Here, we highlight recent advances in 
our understanding of the posttranscrip-
tional regulation of the let-7 miRNA by 
the conserved RNA-binding protein 
Lin28 and show how this impacts our 
understanding of pluripotency, develop-
ment, and cancer. 
Lin28 was first characterized in the 
nematode Caenorhabditis elegans as 
an important regulator of developmental 
timing (Ambros and Horvitz, 1984; Moss 
et al., 1997). Mutations in the lin-28 gene 
and in other so-called “heterochronic 
genes” perturb developmental progres-
sion in the worm, such that character-
istic events occur either earlier or later 
than normal. The mammalian homologs 
of lin-28, Lin28 and Lin28b, bind to the 
terminal loops of the precursors of let-7 
family miRNAs and block their process-
ing into mature miRNAs (Heo et al., 2008; 
Newman et al., 2008; Rybak et al., 2008; 
Viswanathan et al., 2008; Piskounova et 
al., 2008). Interestingly, let-7 is itself a 
heterochronic gene in the worm, sug-
gesting that the interaction between 
Lin28 and let-7 is important for regulat-
ing the timing of development.
Lin28, Reprogramming, and 
 Pluripotency
Both lin-28 and let-7 are highly conserved 
across evolution (Moss et al., 1997; Pas-
quinelli et al., 2000), and recent data are 
beginning to uncover roles for Lin28 in 
mammalian development. Several groups 
have reported the reprogramming of adult 
human fibroblasts to induced pluripotent 
stem (iPS) cells using the same combina-
tion of factors (OCT4, SOX2, KLF4, and 
c-MYC) originally discovered and used by 
Shinya Yamanaka to reprogram mouse 
fibroblasts back to a pluripotent state. 
However, James Thomson’s group cre-
ated iPS cells from adult human fibro-
blasts using a slightly different cocktail of 
factors: OCT4, SOX2, NANOG, and LIN28 
(reviewed in Yamanaka, 2008). Together 
with recent evidence that Lin28 represses 
the processing of a let-7 precursor into 
the mature let-7 miRNA, this raises the 
tantalizing possibility that repression of 
let-7 is important in establishing the pluri-
potent state.
In support of this notion, the let-7 miRNA 
is present in low amounts or is absent in 
a variety of different stem and progenitor 
cell populations. Furthermore, as organ-
isms age, the self-renewal capacity of their 
neural stem cells declines, apparently due 
to an increase in let-7 and a corresponding 
decrease in the expression of HMGA2, a 
target gene that is silenced by let-7 (Nishino 
et al., 2008). Mature miRNAs of the let-7 
family are poorly expressed in undifferenti-
ated embryonic stem cells (ESCs) but their 
primary let-7 precursor transcripts are 
readily detected (Thomson et al., 2006).
This suggests that mature let-7 miRNAs 
are maintained at low levels posttranscrip-
tionally in ESCs and their target genes are 
not repressed. Recent evidence suggests 
that let-7 opposes the actions of a family 
of ESC cell-cycle-regulating miRNAs that 
maintain self-renewal (Melton et al., 2010). 
In the reprogramming cocktail used by Yu 
et al. (2007), LIN28 functionally replaces 
c-MYC, and c-MYC is a known target of 
let-7 (Kumar et al., 2007), which supports 
the notion that LIN28 promotes repro-
gramming by preventing production of 
mature let-7 miRNAs. Several reports also 
indicate that Lin28 can affect protein levels 
by regulating mRNA stability (Polesskaya 
et al., 2007; Xu et al., 2009; Qiu et al., 2009), 
and that Lin28 directly promotes the trans-
lation of OCT4 mRNA (Qiu et al., 2009) and 
may modulate cell proliferation by enhanc-
ing the translation of various cell-cycle 
regulators in mouse ESCs (Xu et al., 2009). 
Therefore, Lin28 may promote reprogram-
ming through both miRNA-dependent and 
miRNA-independent pathways. In some 
cases, it is also possible that regulation of 
mRNA stability may be a secondary con-
sequence of Lin28-mediated modulation 
of miRNA processing.
Lin28 and Cancer
In addition to c-MYC, several other onco-
genes are known to be targets of let-7, 
including K-Ras and cyclin D1 (reviewed 
in Roush and Slack, 2008). Therefore, 
let-7 may act as a tumor suppressor 
miRNA, and its loss has been linked to 
Lin28: A MicroRNA Regulator  
with a Macro Role
Srinivas R. Viswanathan  and George Q. Daley1 1,*
1Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Children’s Hospital Boston and Dana Farber Cancer 
Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, and the Howard Hughes Medical 
Institute, Boston, MA 02115, USA
*Correspondence: george.daley@childrens.harvard.edu
DOI 10.1016/j.cell.2010.02.007
Lin28, a highly conserved RNA-binding protein, has emerged as a modulator of the processing 
of the let-7 microRNA. This role for Lin28 has important implications for our mechanistic under-
standing of pluripotency, the timing of development, and oncogenesis.
446 Cell 140, February 19, 2010 ©2010 Elsevier Inc.
oncogenesis (Johnson et al., 
2005; Takamizawa et al., 2004). 
Mammalian genomes contain 
multiple let-7 family members 
processed from distinct pre-
cursor transcripts. In settings 
where let-7 family members 
are coexpressed and show 
functional redundancy, genetic 
events that inactivate individual 
let-7 members may not have 
dramatic phenotypic conse-
quences. However, given that 
LIN28/LIN28B regulates all let-7 
family miRNAs, could LIN28/
LIN28B contribute to onco-
genesis by coordinately inacti-
vating let-7 family miRNAs? We 
have found that LIN28/LIN28B 
can promote transformation 
by repressing let-7 miRNAs, 
and that activation of LIN28/
LIN28B occurs in many differ-
ent human tumors with a fre-
quency of ?15% (Viswanathan 
et al., 2009).
It is indeed intriguing, but 
perhaps no coincidence, that 
all currently described repro-
gramming factors—OCT4, 
SOX2, KLF4, c-MYC, NANOG, 
and LIN28—have been linked 
to oncogenesis. This under-
scores the notion that the 
complex genomic repro-
gramming that accompanies 
induced pluripotency shares 
many commonalities with the complex, 
albeit aberrant, genomic reprogramming 
that accompanies neoplastic transfor-
mation. Strikingly, LIN28 and LIN28B 
are specifically activated in the subset of 
tumors that are poorly differentiated and 
carry the worst prognosis (Viswanathan 
et al., 2009). Aggressive, high-grade 
tumors are frequently characterized by 
impaired differentiation, and patholo-
gists often use the differentiation status 
of a tumor as a metric for scoring cancer 
severity. When expressed in the proper 
genetic and epigenetic context, LIN28 
together with OCT4, SOX2, and NANOG 
can promote the reprogramming of a 
terminally differentiated cell to a pluripo-
tent ESC-like cell. But when aberrantly 
expressed, LIN28/LIN28B may contrib-
ute to the development of an aggressive, 
poorly differentiated tumor. Indeed, a 
recent report suggests that several dif-
ferent types of aggressive poorly dif-
ferentiated tumors, including basal-like 
breast cancers and high-grade bladder 
carcinomas, express an ESC-like gene 
signature (Ben Porath et al., 2008).
Poorly differentiated tumors might 
arise either from stem or progenitor cells 
that acquire additional malignant hits or 
from somatic cells that dedifferentiate 
by activating components of the pluripo-
tency machinery (Figure 1). In the case 
of LIN28B, rare amplification or translo-
cation events might explain activation in 
some cases (Viswanathan et al., 2009). 
A more common mechanism, however, 
might be transcriptional activation by 
an upstream factor or factors during 
tumor progression. In support of this 
notion, c-Myc binds to both the Lin28 
 (Dangi-Garimella et al., 2009) and LIN28B 
(Chang et al., 2009) loci and 
activates expression of these 
genes. However, c-Myc acti-
vation in tumors is far more 
common than LIN28/LIN28B 
activation—the need for tran-
scriptional coactivators or 
epigenetic inaccessibility of 
the LIN28/LIN28B loci may 
explain this. Finally, in some 
cases, LIN28/LIN28B may be 
expressed in a rare somatic 
progenitor cell of origin that 
becomes transformed (Figure 
1). Regardless of the mecha-
nism of activation, which may 
vary from tumor to tumor, 
cancers expressing LIN28/
LIN28B appear to be depen-
dent on these proteins for 
growth (Chang et al., 2009; 
Dangi-Garimella et al., 2009; 
Viswanathan et al., 2009).
The precise manner by 
which LIN28 contributes to 
tumorigenesis presents a 
compelling avenue for future 
investigation, and there are 
several intriguing possibili-
ties. Rare breast tumor-initiat-
ing cells express low levels of 
all let-7 family miRNAs (Yu et 
al., 2007). Meanwhile reduced 
let-7 levels have been shown 
to confer radioresistance, 
whereas increased let-7 lev-
els confer radiosensitivity 
(Weidhaas et al., 2007). Knocking down 
LIN28B expression in a radioresistant 
lung cancer cell line increased let-7 levels 
and decreased expression of K-RAS, a 
let-7 target, resulting in enhanced radio-
sensitivity (Jeong et al., 2009). Therefore, 
tumor-initiating cells expressing LIN28/
LIN28B may persist after chemotherapy 
and may seed relapse in some patients.
Emerging evidence suggests that 
HMGA2, another target of let-7, actively 
promotes the epithelial-to-mesenchymal 
transition (EMT), a key event in develop-
ment and metastasis (Dangi-Garimella et 
al., 2009; Shell et al., 2007). The obser-
vation that LIN28 and LIN28B are spe-
cifically activated in advanced stage and 
high-grade tumors suggests that they 
play a role later during tumorigenesis. 
Furthermore, Lin28 and let-7 have been 
placed directly within a metastasis sig-
Figure 1. Let-7 in Development and Tumorigenesis
(Top) During normal development, the RNA-binding protein Lin28 is highly 
expressed in stem and progenitor cells. Lin28 blocks processing of let-7 
 microRNA (miRNA) precursor molecules into mature miRNAs , thereby main-
taining expression of genes that drive self-renewal and proliferation. As pro-
genitor cells differentiate, Lin28 expression decreases, which allows let-7 
processing and increased production of mature let-7 miRNAs. Let-7 miRNAs 
repress the expression of genes involved in self-renewal resulting in lineage 
commitment and terminal differentiation. 
(Bottom) Tumors that express Lin28 might arise in two ways. A stem/progeni-
tor cell expressing Lin28 could become transformed through acquisition of 
several genetic mutations. Alternatively, a somatic cell that has been trans-
formed through acquisition of genetic mutations could activate Lin28 expres-
sion, through genetic or epigenetic mechanisms, in the later stages of tumori-
genesis. Lin28-positive tumors are poorly differentiated and more aggressive 
than Lin28-negative tumors.
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naling cascade (Dangi-Garimella et al., 
2009). Notably, Lin28 shares many paral-
lels with Twist, a factor recently identified 
as an inducer of EMT and a key media-
tor of metastasis (Dangi-Garimella et al., 
2009; Mani et al., 2008). Both Lin28 and 
Twist are encoded by developmentally 
regulated genes, are associated with 
advanced malignancy and regulatory cir-
cuits involving c-Myc, and both strongly 
cooperate with other oncogenes in 
assays of cell transformation (Mani et al., 
2008; Valsesia-Wittmann et al., 2004). 
Elucidating whether LIN28 and LIN28B 
have a direct role in promoting metasta-
sis is a potentially rewarding avenue for 
future work.
Several studies place Lin28/Lin28b 
within an important regulatory network 
involving c-Myc and let-7 (Chang et 
al., 2009; Dangi-Garimella et al., 2009). 
Lin28/Lin28b represses let-7, which is 
itself able to repress Lin28/Lin28b by 
binding to the 3′UTR of Lin28/Lin28b 
transcripts, thus forming a double-neg-
ative-feedback loop. A second feedback 
loop exists between Lin28 and c-Myc: 
Lin28/Lin28b derepresses c-Myc by 
repressing let-7, and c-Myc transcrip-
tionally activates both Lin28 and Lin28b 
(Chang et al., 2009; Dangi-Garimella 
et al., 2009). Notably, derepression of 
c-Myc might also contribute to the tran-
scriptional repression of diverse miRNAs 
and transcriptional activation of certain 
oncogenic miRNAs (Chang et al., 2008). 
This Lin28/let-7/c-Myc loop may partially 
explain the widespread deregulation of 
miRNAs observed in many human malig-
nancies (Lu et al., 2005).
There is also a positive-feedback loop 
involving NF-κB, Lin28b, let-7, and IL-6: 
NF-κB induces expression of Lin28b, 
leading to repression of let-7 and expres-
sion of the gene encoding IL-6 (a let-7 
target). IL-6 can itself activate NF-κB, 
completing a positive-feedback loop. In 
an experimental system, transient induc-
tion of the Src tyrosine kinase activates 
NF-κB and initiates this positive-feed-
back loop, resulting in neoplastic trans-
formation. This loop operates in cancer 
cell lines and breast tumor-initiating 
cells and has been suggested to link the 
inflammatory response, of which IL-6 is 
a component, to cancer (Iliopoulos et al., 
2009). Both of these loops may function 
in normal development: double negative-
feedback loops have been postulated 
to play a central role in gene regulatory 
networks by forming “bistable switches” 
that reinforce binary cell fate decisions 
(Martinez et al., 2008).
Lin28: A Developmental Regulator
Several genome-wide association stud-
ies (GWAS) have implicated LIN28B 
as a regulator of human development. 
Hirschhorn and colleagues identified 
markers near 12 loci that account for 
2% of the population variation in human 
height; 1 of the 12 loci identified was 
Figure 2. The Lin28/let-7 Regulatory Loop
In pluripotent cells or transformed cells, the Lin28 locus is epigenetically accessible and poised for transcriptional activation by pluripotency or oncogenic tran-
scription factors. The Lin28 protein may be posttranslationally modified by phosphorylation, ubiquitination, or other modifications, which may affect its subcel-
lular localization and activity. In the presence of Lin28, the pre-let-7 precursor is uridylated by TUT4 and targeted for degradation, thus blocking its processing 
into the mature let-7 miRNA. This leads to derepression of let-7 target genes, including oncogenes such as Ras and c-Myc and cell-cycle genes such as cyclin 
D1 and cyclin D3. In differentiated cells or nontransformed cells, the lin28 locus is epigenetically inaccessible or the factors that transcriptionally activate lin28 
are not present. In the absence of Lin28, the pre-let-7 precursor can be efficiently processed into mature let-7 miRNAs, which block expression of pro-mitogenic 
factors (e.g., Ras, c-Myc, HMGA2), and factors involved in cell-cycle progression (cyclin D1, cyclin D3, cdk4) and maintenance of the pluripotent or multipotent 
state (e.g., Blimp-1). Upon initiation of differentiation, let-7 miRNA targets the lin28 mRNA for posttranscriptional repression (dotted arrow), further relieving 
repression of pre-let-7 precursor processing and establishing a positive-feedback loop that helps to promote differentiation.
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LIN28B, and several other loci encode 
let-7 targets (Lettre et al., 2008). More 
recently, several independent GWAS 
have identified common polymorphisms 
near LIN28B as being associated with a 
woman’s age at menarche (reviewed in 
Hartge, 2009). Together with established 
data in the worm, the identification of 
relevant human genetic variations sug-
gests that the Lin28/let-7 axis may be an 
important regulator of cell growth and 
development in evolutionarily distant 
organisms. Subtle variations in the activ-
ity of this pathway may result in height 
or size differences among individuals of 
the same species, and more dramatic 
perturbations of this pathway may drive 
oncogenesis. Thus, Lin28/Lin28b may be 
similar to PI3-kinase, mTOR, and com-
ponents of the Hippo pathway, which 
contribute to the regulation of organ 
growth and size and may be deregulated 
in some cancers.
Several recent reports suggest that 
Lin28 may cooperate with a terminal 
uridylyl transferase (TUTase) to regulate 
blockade of let-7 production (Figure 2). 
Lin28 and Lin28b are associated with a 
TUTase activity that results in the addi-
tion of a poly-U tail to the let-7 precursor, 
pre-let-7 (Heo et al., 2008). Uridylated 
pre-let-7 cannot be efficiently processed 
by the enzyme Dicer and is targeted for 
degradation. Three groups have now 
identified the enzyme responsible for 
this activity in both mammalian cells 
(TUT4/zcchc11) (Heo et al., 2009; Hagan 
et al., 2009) and in C. elegans (PUP-2) 
(Lehrbach et al., 2009). Together, these 
reports outline an evolutionarily ancient 
pathway in which Lin28 recognizes pre-
let-7 via a motif in its terminal loop and 
recruits a TUTase to mark pre-let-7 for 
degradation. Lin28/TUT4-mediated uri-
dylation of other pre-miRNAs with similar 
loop motifs has also been reported (Heo 
et al., 2009). Given that polymerases are 
facile targets for pharmacological inhibi-
tion by small molecules, TUT4 may prove 
to be an attractive pharmaceutical target 
for manipulating the LIN28/let-7 axis in 
cancer cells.
The terminal loops of miRNA precur-
sors serve essential regulatory roles 
(Trabucchi et al., 2009; Michlewski 
et al., 2008; Guil and Caceres, 2007; 
Piskounova et al., 2008); for example, 
hnRNPA1 binds to the terminal loop 
of pri-miR-18a and enhances Drosha-
mediated processing of this precursor 
into the mature miRNA (Guil and Cac-
eres, 2007). The RNA-binding protein 
KSRP binds to the terminal loop of a 
subset of miRNAs, including let-7, and 
enhances their processing (Trabucchi 
et al., 2009). Indeed, it is quite likely that 
the expression of many miRNAs is con-
trolled at the level of processing, with 
the terminal loop serving as a point of 
regulation (Michlewski et al., 2008). The 
factors that control miRNA biogenesis 
are likely to confer an additional layer 
of precision, complexity, and versatility 
to gene regulation. The therapeutic tar-
geting of such regulatory factors may be 
a viable strategy to reduce or enhance 
the expression of specific miRNAs in the 
setting of human disease.
Recent studies of Lin28 and let-7 have 
highlighted the fact that normal develop-
ment, somatic cell reprogramming, and 
oncogenesis share common pathways. 
Going forward, it will be critical to define 
precise roles for Lin28/Lin28b in each 
of these settings. This will allow us to 
understand how the Lin28/let-7 pathway 
functions in physiological development, 
how it is deregulated during tumorigen-
esis, and how it can be experimentally 
exploited to enhance the production of 
pluripotent cells. More broadly, further 
investigation of the Lin28/let-7 partner-
ship may lend insight into the mecha-
nisms and consequences of the regula-
tion of miRNA expression by trans-acting 
factors.
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